OncUpdates
  • Conferences
    • ASCO
      • Rapid Reactions
      • Breast Cancer
      • GI Cancer
      • GU Cancer
      • Head and Neck Cancer
      • Hematology
      • Lung Cancer
    • ASCO GI
      • Biliary/Liver Cancer
      • Colorectal Cancer
      • Gastric/GEJ Cancer
      • General GI Cancer
      • Pancreatic Cancer
    • ASCO GU
      • Bladder Cancer
      • General GU Oncology
      • Prostate Cancer
      • RCC
    • ASH
      • General Hematology
      • Leukemia
      • Lymphoma
      • Multiple Myeloma
    • EHA
    • ESMO
      • Breast Cancer
      • GI Oncology
      • GU Oncology
      • Lung Cancer
    • SABCS
      • General Breast Cancer
      • HER2-Positive Breast Cancer
      • HR+ Disease
      • TNBC
    • WCLC
  • Videos & Podcasts
    • Challenging Cases
      • Breast Cancer
      • GU Oncology
      • Hematology
      • Lung Cancer
    • New Approvals
      • Breast Cancer
      • GI Oncology
      • GU Oncology
      • Hematology
      • Lung Cancer
    • Tox Check
      • Breast Cancer
      • GI Oncology
      • GU Oncology
      • Hematology
      • Lung Cancer
    • Treatment Algorithms
      • Breast Cancer
      • Dermatology
      • GI Oncology
      • GU Cancer
      • Head and Neck Cancers
      • Hematology
      • Lung Cancer
      • Ovarian Cancer
  • Clinical Insights
    • Breast Cancer
      • Early HR+
      • Metastatic HR+
    • GI Oncology
      • Gastric/GEJ Cancer
      • Pancreatic Cancer
    • GU Oncology
      • Bladder Cancer
      • RCC
    • Head & neck cancers
    • Hematology
      • Leukemia
      • MDS
      • Multiple Myeloma
      • Polycythemia Vera
    • Lung Cancer
      • NSCLC
      • SCLC
  • Resource Centers
    • Cell Therapy
    • Metastatic Breast Cancer
    • Pancreatic Cancer
  • Articles
    • Breast Cancer
    • General News
    • GI Oncology
    • GU Oncology
    • Hematology
    • Lung Cancer
  • Events
  • Subscribe
OncUpdates
  • Conferences
    • ASCO
      • Rapid Reactions
      • Breast Cancer
      • GI Cancer
      • GU Cancer
      • Head and Neck Cancer
      • Hematology
      • Lung Cancer
    • ASCO GI
      • Biliary/Liver Cancer
      • Colorectal Cancer
      • Gastric/GEJ Cancer
      • General GI Cancer
      • Pancreatic Cancer
    • ASCO GU
      • Bladder Cancer
      • General GU Oncology
      • Prostate Cancer
      • RCC
    • ASH
      • General Hematology
      • Leukemia
      • Lymphoma
      • Multiple Myeloma
    • EHA
    • ESMO
      • Breast Cancer
      • GI Oncology
      • GU Oncology
      • Lung Cancer
    • SABCS
      • General Breast Cancer
      • HER2-Positive Breast Cancer
      • HR+ Disease
      • TNBC
    • WCLC
  • Videos & Podcasts
    • Challenging Cases
      • Breast Cancer
      • GU Oncology
      • Hematology
      • Lung Cancer
    • New Approvals
      • Breast Cancer
      • GI Oncology
      • GU Oncology
      • Hematology
      • Lung Cancer
    • Tox Check
      • Breast Cancer
      • GI Oncology
      • GU Oncology
      • Hematology
      • Lung Cancer
    • Treatment Algorithms
      • Breast Cancer
      • Dermatology
      • GI Oncology
      • GU Cancer
      • Head and Neck Cancers
      • Hematology
      • Lung Cancer
      • Ovarian Cancer
  • Clinical Insights
    • Breast Cancer
      • Early HR+
      • Metastatic HR+
    • GI Oncology
      • Gastric/GEJ Cancer
      • Pancreatic Cancer
    • GU Oncology
      • Bladder Cancer
      • RCC
    • Head & neck cancers
    • Hematology
      • Leukemia
      • MDS
      • Multiple Myeloma
      • Polycythemia Vera
    • Lung Cancer
      • NSCLC
      • SCLC
  • Resource Centers
    • Cell Therapy
    • Metastatic Breast Cancer
    • Pancreatic Cancer
  • Articles
    • Breast Cancer
    • General News
    • GI Oncology
    • GU Oncology
    • Hematology
    • Lung Cancer
  • Events
  • Subscribe

MIBC

Home / Clinical Insights / GU Oncology / Bladder Cancer / MIBC

ASCO GU 2026

View All
Advanced multidisciplinary approaches to emerging bladder cancer treatments featuring leading experts Dr. Matt Galsky, Dr. Sia Daneshmand, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Chad Reichard, and Dr.

ASCO GU 2026

03/15/2026

Ep. 4: Multidisciplinary Approaches to Emerging Bladder Cancer Treatments

Rahul Gosain, MD, MBARohit Gosain, MDMatt Galsky, MDSia Daneshmand, MDChad Reichard, MDShilpa Gupta, MD
Advanced medical team discussing innovative approaches to perioperative ADC and immunotherapy in muscle-invasive bladder cancer.

ASCO GU 2026

03/14/2026

Ep. 3: Optimizing Perioperative ADC and Immunotherapy in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBARohit Gosain, MDMatt Galsky, MDSia Daneshmand, MDChad Reichard, MDShilpa Gupta, MD
Advanced cancer specialists discussing systemic therapy and radical cystectomy in MIBC at OncUpdates conference. Expert panel includes Dr. Matt Galsky, Dr. Sia Daneshmand, Dr. Chad Reichard, Dr. Shilp.

ASCO GU 2026

03/12/2026

Ep. 2: Coordinating Systemic Therapy and Radical Cystectomy in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBARohit Gosain, MDMatt Galsky, MDSia Daneshmand, MDChad Reichard, MDShilpa Gupta, MD
Shifting the Treatment Landscape in MIBC with Expert Oncologists and Innovative Approaches for Bladder Cancer Management.

ASCO GU 2026

03/11/2026

Ep. 1: NIAGARA: Shifting the Treatment Landscape in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBARohit Gosain, MDMatt Galsky, MDShilpa Gupta, MDSia Daneshmand, MDChad Reichard, MD
Expert panel discussing evolving clinical insights in bladder cancer with Dr. Shilpa Gupta, Dr. Chad Reichard, Dr. Sia Daneshmand, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Matt Galsky.

ASCO GU 2026

03/09/2026

Clinical Insights: Evolving Landscapes in MIBC and NMIBC

Rahul Gosain, MD, MBARohit Gosain, MDShilpa Gupta, MDChad Reichard, MDSia Daneshmand, MDMatt Galsky, MD

NIAGARA at ASCO 2025

View All
Expert panel discussion on cancer research and oncology advancements at OncUpdates.

NIAGARA at ASCO 2025

06/16/2025

EP. 6: Practice-Changing Insights From the NIAGARA Trial

Petros Grivas, MD, PhD

NIAGARA in the EV + IO Era

View All
Medical professionals Dr. Raji Shameem, Dr. David H. Aggen, Dr. Alexandra Drakaki, and Dr. Ashish M. Kamat discuss personalized perioperative treatment for MIBC with NIAGARA and EV-based regimens.

NIAGARA in the EV + IO Era

07/31/2026

Ep. 4: Personalizing Perioperative Treatment for Muscle-Invasive Bladder Cancer With NIAGARA and EV-Based Regimens

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD
Medical professionals discussing perioperative therapy for MIBC based on patient and tumor characteristics in a hospital setting.

NIAGARA in the EV + IO Era

07/30/2026

Ep. 3: Selecting Perioperative Therapy for Muscle-Invasive Bladder Cancer Based on Patient and Tumor Characteristics

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD
Medical professionals discussing perioperative MIBC interpreting pCR, survival, and treatment options in a hospital setting.

NIAGARA in the EV + IO Era

07/26/2026

Ep. 2: Perioperative Muscle-Invasive Bladder Cancer: Interpreting pCR, Survival, and Treatment Selection

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD
Panel discussion on NIAGARA and EV-Based Perioperative Therapy Reshaping MIBC Treatment with Dr. Raji Shameem, Dr. David H. Aggen, Dr. Alexandra Drakaki, and Dr. Ashish M. Kamat.

NIAGARA in the EV + IO Era

07/24/2026

Ep. 1: NIAGARA and EV-Based Perioperative Therapy Reshape Treatment for Muscle-Invasive Bladder Cancer 

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD
Medical professionals discussing redefining perioperative bladder cancer treatment with NIAGARA in the EV + IO era.

NIAGARA in the EV + IO Era

07/23/2026

Experts Review Perioperative Regimens and Potential Future Strategies for Resectable MIBC

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD

Perioperative Durvalumab for MIBC

View All
Discussion panel on oncology research at OncUpdates, featuring medical experts sharing insights on cancer treatment advancements and latest breakthroughs in oncology.

Perioperative Durvalumab for MIBC

06/16/2025

Ep. 5: NIAGARA Trial: Perioperative Durvalumab Enhances DFS in MIBC

Joshua Meeks, MD, PhD
Expert panel discussion on oncology research and recent advancements in cancer treatment.

Perioperative Durvalumab for MIBC

06/16/2025

Ep. 4: The Oncologist’s Role in Counseling Patients With MIBC Through Complex Treatment Decisions

Karine Tawagi, MD
High-level discussion on oncology research and cancer treatment advancements at OncUpdates conference. Experts share insights on innovative therapies and patient care strategies.

Perioperative Durvalumab for MIBC

06/16/2025

Ep. 3: Key Takeaways From the NIAGARA Trial for Patients With MIBC

Neal Shore, MD, FACS
Lecture on cancer treatment innovations discussed among medical professionals.

Perioperative Durvalumab for MIBC

06/16/2025

Ep. 2: Clinical Implications of Circulating Tumor DNA in MIBC

Petros Grivas, MD, PhDJoshua Meeks, MD, PhD
In-depth interview with medical experts discussing latest advancements in cancer treatment and research, focusing on patient care, innovative therapies, and clinical trial updates.

Perioperative Durvalumab for MIBC

06/16/2025

Ep. 1: Current Treatment Strategies for Muscle-Invasive Bladder Cancer

Karine Tawagi, MD
1. Expert oncologists presenting research on NIAGARA trial and perioperative durvalumab treatment for MIBC.

Perioperative Durvalumab for MIBC

06/14/2025

NIAGARA Trial: Perioperative Durvalumab for MIBC (Full Video)

Joshua Meeks, MD, PhDKarine Tawagi, MDNeal Shore, MD, FACSPetros Grivas, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Stay Ahead with the Latest Oncology Insights

Quick links

  • About Us
  • Upcoming Events
  • Contact Us
  • Authors

Legal

  • Terms And Conditions
  • Cookie Policy
  • Privacy Policy
Subscribe To Our Newsletters
  • Subscribe
SignifyMD LLC
PO Box 512, Brielle, NJ 08730

Property of SignifyMD LLC, All Rights Reserved 2026

Oncology Resources | Hematology Support | Community Oncology